Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 2 pages · Chinese
Release
Hunan Fangsheng Pharmaceutical Co., Ltd. on 6ix
Earlier from Hunan Fangsheng Pharmaceutical
- Announcement on Obtainment of the "Drug Registration Certificate" for Silapage Tablets
- Announcement on Obtaining Drug Registration Certificate for Bisoprolol Amlodipine Tablets
- Announcement on Continuation of Procurement for Products Selected in Centralized Procurement Agreements Upon Expiration of Agreement Period
- Announcement on Soliciting Investor Opinions on Matters Related to 2025 Profit Distribution
- Announcement on Pledge of Partial Shares of Controlling Shareholder
Later from Hunan Fangsheng Pharmaceutical
- 2025 Annual Report
- Announcement on Outline of the 2025 Annual and Q1 2026 Performance Briefing
- Announcement on Obtaining Summary Report of Phase III Clinical Trial for Pediatric Jingxing Anti-tussive Granules in Adults with Acute Tracheobronchitis (Syndrome of Wind-cold Transformation into Heat)
- Announcement on Proposed Inclusion of Company Products in the Centralized Volume Procurement of National Chinese Patent Medicine Procurement Alliance
- Announcement on Resolutions of the 2025 Annual General Meeting
Follow Hunan Fangsheng Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Fangsheng Pharmaceutical